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Background: The purpose of this study was to draw conclusions from patient-reported 
 experiences in two national surveys from Scandinavia with the intention of comparing treat-
ment strategies and increasing our knowledge of factors that affect the experiences of patients 
with Parkinson’s disease (PD).
Methods: A total of 2000 individuals in Sweden and 1300 in Norway were invited to com-
plete postal surveys covering PD-related issues. Patient experiences of diagnostic procedures, 
symptom control, and follow-up in PD and the effects on symptom-related quality of life were 
collected. Pharmaceutical prescription data on anti-PD drugs and administrative data were col-
lected from national registries.
Results: The surveys were completed by 1553 (78%) of the Swedish cohort and 1244 (96%) of 
the Norwegian cohort. Only small differences were seen in disease duration and age  distribution. 
Statistically as well as clinically significant differences in symptom control, diagnostic, and 
follow-up procedures, as well as in pharmacological treatment and impact on quality of life, 
were found between the national cohorts independent of disease duration.
Conclusion: Information from separate national surveys has the potential to increase our 
knowledge of patient experiences in PD and can be used to compare, evaluate, educate, and guide 
health care staff and administrators in optimizing health care for patients with the disease.
Keywords: parkinson’s disease, diagnosis, follow-up, pharmaceutical prescription, quality of 
life, survey
Introduction
Parkinson’s disease (PD) is a geographically widespread, progressive, chronic neurode-
generative disorder resulting in motor and nonmotor symptoms.1 PD is not uncommon, 
and has a prevalence ranging from 0.3% to 1%–2% among persons aged 65 years and 
older.2 In two Scandinavian studies from 2008 and 2009, the estimated annual incidence 
in Norway was 12.6 per 100,000 inhabitants (95% confidence interval 11.1–14.2), 
while the age-adjusted annual incidence rate in a Swedish study was estimated to be 
21.5 per 100,000 (95% confidence interval 17.4–25.6).3,4 The prevalence of PD in the 
Scandinavian countries in the northern part of Europe is estimated to be 0.175% of 
the total population.5 At the time of the surveys used in this study (2005 and 2006), 
Norway had a population of 4.7 million inhabitants,6 with an estimate of just over 
8000 patients with PD. The corresponding figures for Sweden were 9.1 million and 
just less than 16,000 estimated patients with PD.
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
239
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/JMDH.S44451
Journal of Multidisciplinary Healthcare 2013:6
The pharmacological approach to treating PD has 
advanced in recent decades. From levodopa as the only 
effective pharmacological treatment of the disease in the 
early 1960s,7 other compounds such as enzyme inhibitors and 
dopamine agonists have evolved. Pharmacoepidemiological 
data also show that the traditional patterns of prescribing 
differ between countries.8
National health care systems in different countries face 
different challenges, largely due to their varying economic 
and political conditions, but also because of strict demo-
graphic and geographical factors. A predicted increase in life 
expectancy9 will most probably result in a growing number 
of elderly patients with PD and accompanying health care 
costs.10 As the prevalence of chronic disorders such as PD 
rises, the burden on relatives of sufferers also increases.11,12 
Therefore, providers of managed care and health care plan-
ners need a broad understanding of PD and its management, 
as well as good insights into prescribing habits and cost-
benefit analyses.13
All these facts stress the need for a systematic evalua-
tion of the therapies that are implemented today. However, 
our knowledge about how symptom control is influenced 
by additional, often costly, pharmacological prescriptions is 
insufficient. Patient adherence with the medication regimen 
is also critical to treatment outcome.14
Further, we also lack an adequate understanding of how 
different organizational approaches influence patient expe-
riences with treatment of their PD over time. The lifelong 
burden of a disease is influenced by many factors, only a 
few of which are possible to capture on general levels. In a 
new era of rapid and often digitalized communication, the 
opportunities to collect data from large anonymous cohorts 
of patients have increased. Therefore, we decided to compile 
data from two national surveys in an attempt to broaden our 
understanding of this field and discover new perspectives.
The primary aim of this study was to consider the general 
usefulness of national surveys by comparing patients’ self-
reported answers from two examples. The secondary aim was 
to compare the effects of differences in diagnostic procedures 
and anti-Parkinson pharmaceutical prescribing patterns on 
self-reported patient experiences of symptom control and 
symptom-related quality of life in Sweden and Norway.
Patients and methods
A total of 2000 Swedish patients with PD were asked 
to answer a questionnaire attached to the Journal of the 
 Swedish Parkinson’s Disease Association. In the same way, 
1300 Norwegian patients with PD were asked to answer a 
 corresponding questionnaire in the Journal of the Norwegian 
Parkinson’s Disease Association. Patients were randomly cho-
sen and account for one third of subscribers to the journal. The 
figures also correspond to 9.8% and 16.1% of the estimated 
PD populations of Sweden and Norway, respectively.
Both surveys contained questions on demographics as 
well as individual disease data with regard to diagnosis, 
treatment, and follow-up. The impact on quality of life due 
to symptoms of PD was assessed using a global measure on 
a five-point Likert scale ranging from little impact to high 
impact (“Are the symptoms from your Parkinson disease 
affecting your quality of life in a negative way?”).15
The pharmacological profile of anti-PD medication in 
Sweden for the actual year was collected from the national 
pharmaceutical database.16 Data concerning the correspond-
ing pharmacological profile in Norway were extracted from 
the prescription database at the Norwegian Institute of Public 
Health.17
Before commencing the study, approval was secured 
from the ethics committee at the University of Linköping, 
Sweden (2010/62-31). In a covering letter to respondents, it 
was stated that all results would be processed anonymously 
and presented in a nonidentifiable way. No identification data 
were used in the database. Because most data were in ordinal 
scales, nonparametric statistics were used. The Chi-square 
test, Mantel-Haenszel Chi-square, and Fisher’s Exact test 
were used as appropriate.
Results
Demographic data
Figure 1A show the age distribution of members of the 
Swedish and Norwegian   Parkinson’s Disease Associations. 
Median age was 71 (25th/75th percentiles) (67/77) years 
of the respondents. The oldest members of the association 
(.80 years) were less likely to participate in the survey. 
Median (25th/75th percentile) age at onset of disease was 
61 (55/69) years in the Swedish cohort and 62 (54/68) years 
in the Norwegian cohort. Corresponding values for duration 
of disease in the Swedish and Norwegian cohorts were eight 
(5/13) and eight (4/12) years.
Diagnosis and follow-up
In both countries, the majority of patients were diagnosed by 
neurologists. Of the remaining patients, significantly more 
were diagnosed by geriatricians in the Swedish cohort (4%) 
than in the Norwegian cohort (0.6%). General practitioners 
also diagnosed more patients with PD in Sweden than in 
Norway (Table 1).
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Figure 1 (A) Age distribution of respondents in Sweden and Norway versus the age distribution of all members of the Swedish Parkinson’s Disease Association (data from 
the Norwegian Movement Disorders Association not available). (B) Duration of Parkinson’s disease among respondents in the Swedish and Norwegian cohorts.
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In Norway, follow-up of patients with PD was more often 
performed by general practitioners (17% in the Norwegian 
cohort and 7% in the Swedish cohort). The opposite was 
found for geriatricians (0.2% in the Norwegian cohort and 
8% in the Swedish cohort), but according to the respondents, 
the vast majority of patients in both countries were followed 
up by neurologists (91% in the Norwegian cohort and 80% 
in the Swedish cohort). In addition, more than one special-
ist was often in contact with a patient, probably to treat 
concomitant illnesses. Contact between other caregivers and 
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Table 1 Specialists diagnosing Parkinson’s disease in Sweden and 
Norway
Medical specialty Sweden  
(n)
(%) Norway  
(n)
(%) Chi-square 
test
Neurologist 1209 73.5 1144 86.8 P , 0.0001
Geriatrician 64 4.0 8 0.6 P , 0.0001
General practitioner 261 15.9 143 10.8 P , 0.0001
Other specialist 91 5.5 15 1.1 P , 0.0001
Unknown/missing 19 1.1 8 0.7 –
Total 1644 1318
Norway
37%
7%
1%
15%
23%
16%
Sweden
5%
16%
6%
26%
5%
42%
Others*
Selegiline
Levodopa
L-dopa + entacapone
Dopamine agonists
Entacapone
Figure 2 Market shares of antiparkinsonian drugs in Sweden and Norway in defined daily doses for 2008. *Includes carbidopa-levodopa delivered via intraintestinal pump, 
rasagiline, amantadine, and others.
patients also differed between respondents from the different 
countries. Significantly more patients in the Swedish cohort 
(P , 0.0001) made their own contacts and appointments 
with caregivers than in the Norwegian cohort.
Nurses had a more active role in the Swedish cohort, 
with 3% (51/1501) of respondents reporting medication 
adjustments through contact with a PD nurse. Frequencies 
of contacts between caregiver and patient and initiatives to 
the contacts are visualized in Table 2. This was significantly 
different (P = 0.002) from the Norwegian cohort, where only 
1.5% (19/1275) reported medication adjustments without 
contact with their doctor. Neurologists, geriatricians, gen-
eral practitioners, and nurses cooperated more often in dose 
adjustments in the Swedish cohort, 4% (n = 54)  versus 1% 
(n = 13) in the Norwegian cohort. However, in the Norwe-
gian cohort, cooperation between neurologists and general 
practitioners was common, with 12% (n = 159) of respon-
dents reporting this.
Pharmacological therapy
The market shares of anti-PD drugs in Sweden and Norway 
in defined daily doses for the years surveyed are shown 
in Figure 2. Use of different groups of anti-PD drugs 
among respondents to the survey is shown in Figure 3. 
 Levodopa-benserazide or levodopa-carbidopa were most 
commonly used as single therapy in both countries (27% 
in the Swedish cohort and 20% in the Norwegian cohort). 
Levodopa-carbidopa represented a higher proportion in the 
Norwegian cohort, than in the Swedish, and 38% of respond-
ers in Sweden reported using selegiline, a monoamine oxi-
dase B  inhibitor. This contrasts strongly with the Swedish 
cohort, where only 11% reported using selegiline. Even when 
taken in combination with other antiparkinsonian medica-
tions, taking levodopa-benserazide or levodopa-carbidopa 
was slightly more common in the Swedish cohort. Total use 
was 72% in the Swedish cohort compared with 71% in the 
Norwegian cohort.
More than one drug was used by 68% of the Swedish 
respondents and 72% of the Norwegian respondents. The 
most common combination therapy among Swedish respon-
dents was levodopa-benserazide or levodopa-carbidopa and 
pramipexole, which were used by 14% of respondents. In the 
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Figure 3 Antiparkinsonian medication among respondents according to pharmacological group. Note that one patient might have a combination of several drugs. 
Notes: *Catechol-O-MetylTransferas- Inhibitor (COMT I) includes levodopa and tolcapone; **includes amantadine, carbidopa-levodopa delivered via intraintestinal pump, 
rasagiline, and others.
Norwegian cohort, the corresponding proportion was 7%, and 
combination therapies of selegiline and levodopa-carbidopa 
or levodopa-benserazide were most common (reported by 
10% of respondents). This combination therapy was only 
reported by 2.5% of respondents in the Swedish cohort. 
These differences were highly significant (P , 0.0001, 
Fisher’s Exact test).
Motor complications, disease duration, 
and satisfaction with treatment
Wearing off more than once a day was experienced by 
38% in the Norwegian cohort compared with 18% in the 
Swedish cohort. No wearing off or less than one episode per 
day was reported by 243 patients (19%) in the Norwegian 
cohort and 453 (31%) in the Swedish cohort. Once again, 
these differences were significant (P , 0.0001, Fisher’s 
Exact test).
Despite the reported differences in the frequency of motor 
complications, significantly more patients in the Norwegian 
cohort (63%) were satisfied with their medication than those 
in the Swedish cohort (52%, P , 0.0001, Fisher’s Exact test). 
Data were missing for 7% of the Swedish cohort and for 4% 
of the Norwegian cohort.
About one third of respondents reporting satisfac-
tion with medication were prescribed one single drug 
(31% in the Swedish cohort and 36% in the Norwegian 
cohort).  However, most patients reporting satisfaction 
with their pharmacological treatment (38% in the  Swedish 
cohort and 46% in the Norwegian cohort) were pre-
scribed a  combination with two antiparkinsonian drugs. 
 Corresponding answers for respondents prescribed more 
than four different drugs were 13% for the Swedish cohort 
and 2% for the Norwegian cohort.
When comparing satisfaction with medication (“Are you 
satisfied with your present Parkinson medication?”), expe-
riencing symptoms of wearing off, and duration of disease 
in the Norwegian cohort, the following was found: of those 
with a disease duration less than two years, 61% were satis-
fied with their medication (P = 0.02, Fisher’s Exact test); of 
those with a disease duration of 2–6 years, 58% were satis-
fied (P , 0.0001, Fisher’s Exact test); and of those with a 
duration of more than six years, 50% were satisfied. There 
was also a statistically significant association between a 
long disease duration and low satisfaction with medication 
(P , 0.0001, Cochran-Mantel-Haenszel test). The degree 
of satisfaction with medication changes during disease 
progression. Wearing-off as a motor complication increases 
with duration of disease. The differences in satisfaction with 
medication among patients with and without wearing-off is 
illustrated in Table 3.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
243
National surveys of PD treatment strategies
Journal of Multidisciplinary Healthcare 2013:6
For the Swedish cohort, the question was formulated as 
“How satisfied are you with your levodopa  medication?” 
Among those experiencing symptoms of wearing off 
with a disease duration of less than two years, 57% were 
satisfied with their medication (P = 0.04, Fisher’s Exact 
test), among those with a disease duration of 2–6 years, 
33% were  satisfied (P , 0.0001, Fisher’s Exact test), and 
among those with a disease duration of more than six years, 
37% were  satisfied. There was also a statistically signifi-
cant  association between a long disease duration and low 
satisfaction with medication (P , 0.0001, Cochran-Mantel-
Haenszel test).
In the Norwegian respondents, 36% (332/931) reported 
selegiline as one of their prescribed drugs. As shown above, 
this was the most common drug combined with one other 
compound. When combining the Norwegian and Swedish 
cohort data and analyzing respondents with a disease dura-
tion of 2–6 years, selegiline in combination with one other 
drug was used by 63 responders. Wearing off more than 
once daily was experienced by 52% (n = 33) in this group, 
and a significantly larger proportion of responders reported 
dissatisfaction with their medication (80% versus 44%, 
P = 0.02). For a disease duration of more than six years, 
116 responders reported combination therapy of selegiline 
and one other compound. Of the patients in this longer dura-
tion group, 69% (80/116) reported wearing off. Significantly 
more patients (85%, 34/40) were dissatisfied with their 
medication compared with those who were satisfied in this 
longer disease duration group (P = 0.007). Figure 4 depicts 
the answers to the quality of life question of “How do the 
symptoms affect your quality of life” divided by duration of 
disease/country.
Discussion
In this study, we found both clinically and statistically signifi-
cant differences between two neighboring national cohorts 
(Sweden and Norway) regarding patient assessment of their 
symptom-related quality of life; patients with PD in the 
Swedish cohort rated their quality of life higher than those 
in the Norwegian cohort. These differences were significant 
in patients with a disease duration longer than two years. 
This finding could simply be due to demographic differ-
ences in the two PD cohorts rather than a true  difference. 
 However, only small differences were seen in terms of age 
and  disease duration between the two cohorts. In addition, 
PD is a well defined clinical diagnosis18 and there is no reason 
to believe that it should differ between the two countries in 
terms of prevalence, incidence, or spread of disease  severity. 
Percent
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Figure 4 Patient-reported QoL in the Swedish and Norwegian cohorts divided by disease duration. Influence on QoL: 1 = little, 5 = severe (Chi-square test). 
Abbreviation: QoL, quality of life.
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Table 3 Relation between disease duration, motor complications (wearing-off) and satisfaction with medication among PD patients’ 
in Sweden and Norway
Sweden Norway
Wearing off (n) No wearing off (n) Wearing off (n) No wearing off (n)
Duration #2 years
 Satisfied with medication 29 25 27 25
 Dissatisfied with medication 8 7 17 4
 Fisher’s Exact test (P = 1.00) (P = 0.04)
Duration 2–6 years
 Satisfied with medication 204 64 94 78
 Dissatisfied with medication 139 11 68 10
 Fisher’s Exact test (P , 0.0001) (P , 0.0001)
Duration $6 years
 Satisfied with medication 369 65 214 89
 Dissatisfied with medication 320 25 213 22
 Fisher’s Exact test (P , 0.0001) (P , 0.0001)
Note: Statistical method; Fishers Exact test.
Table 2 Contacts patterns between patients and doctors/PD nurses in Sweden and Norway
Sweden (n) (%) Norway (n) (%) Fisher’s 
Exact test
Contacts with doctor
Doctor contact once a year 493 28.7 408 28.2
Doctor contact twice a year 600 35.0 565 39.1
Patient contact with doctor 623 36.3 472 32.7 P = 0.03
Contacts with nurse
Nurse contact 63 12.3 91 21.9
Nurse contact once a year NA* 58 14.0
Nurse contact twice a year NA* 43 10.4
Patient contact with nurse 449 87.7 223 53.7 P , 0.0001
Notes: *Not applicable (NA) this question was missing in the Swedish survey. Statistical method; Fishers Exact test.
 Moreover, Sweden and Norway are two countries with  similar 
socioeconomic profiles.19
When health-related quality of life in patients with PD 
was reviewed by Dowding et al,20 the most effective drug 
treatment was mentioned as one of the specific areas that 
needed to be addressed further. In our study, comparison 
between the two countries revealed substantial differences 
in pharmaceutical profiles, not only in terms of type of PD 
medication, follow-up procedures, dose adjustment, and 
patient satisfaction, but also in symptom-related quality of 
life in the first two years after diagnosis. This study also 
highlights other differences between the two neighboring 
countries that might have an impact on the quality of life 
experienced.
Diagnostics and follow-up
The diagnostic procedure in terms of the professional 
categories involved differed in some ways, as did the 
follow-up procedures. Neurologists most often diag-
nosed PD in both countries. However, in the Swedish 
cohort, geriatricians and general practitioners played a 
more dominant role in the diagnostic process than in the 
Norwegian cohort. One in five patients in the Swedish 
cohort was diagnosed by these specialists compared with 
one in ten in the  Norwegian cohort. These figures should 
be viewed in the light of the fact that about 150 specialists 
in geriatrics, 3000 specialists in general medicine, and 
450 specialists in neurology were working in Norway at 
the time of the study, corresponding to 0.8%, 16%, and 
2.5%, respectively, of the total number of specialists.21 
This contrasts with the approximately 500 geriatricians, 
6000 specialists in general medicine, and 300 neurolo-
gists active in Sweden, corresponding to 2%, 25%, and 
1%, respectively, of all specialists.22 Hence, the Swedish 
population of about nine million inhabitants has a greater 
proportion of specialists in geriatrics available but less 
access to neurologists compared with Norway and its 
4.7 million inhabitants.
More patients in the Swedish cohort made their own 
appointments with their doctor and had independent con-
tact with their PD nurse than in the Norwegian cohort. This 
indicates that the former cohort includes more empowered 
patients and caregivers who actively try to influence and 
improve their situation and quality of life. To a small extent, 
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Swedish nurses are also able to adjust pharmacological 
therapy, which was not the case in Norway. These findings 
could also be related to the greater emphasis on team edu-
cation, self-care, and lifestyle programs stimulated by the 
Swedish health care authorities during recent decades. The 
implications of the differences in the diagnostic and follow-up 
procedures, with a clearer focus on the Swedish respondents’ 
own initiatives and self-responsibility, might contribute to a 
feeling of safety and empowerment. This  feeling, combined 
with access to health professionals, is probably important for 
their perception of quality of life.20
Pharmacological treatments  
and motor complications
Anti-PD medication has been shown to improve the severity 
of motor symptoms and motor complications in advanced 
PD. From a patient’s point of view, there is evidence that this 
can be translated into improved quality of life.23,24 However, 
quality of life is also influenced by a variety of nonmotor 
symptoms, such as depression and sleep disturbance, as well 
as by social interaction and feelings of safety.25
Not surprisingly, comparing patients with short (less 
than or up to two years), medium to long (2–6 years), and 
long (more than six years) duration of PD reveals significant 
differences in the proportion of wearing off episodes. When 
the rates of wearing off symptoms between the two cohorts 
were compared, only limited differences that could explain 
the differences in satisfaction were found.
The national pharmacological databases of each 
country17,26 showed significant differences in the pharmaco-
logical approaches to PD treatment between the cohorts as 
well as between the countries as a whole. For example, sig-
nificantly more use of selegiline was made in the Norwegian 
cohort. Selegiline, as a compound for reducing off-time, has 
been somewhat controversial.27,28
In this study, we had a special focus on combination 
therapy with selegiline because this was the most common 
therapy in the Norwegian cohort. Combining data from the 
Swedish and Norwegian cohorts for this aspect of treatment 
showed that significantly more responders with a disease 
duration longer than two years reported dissatisfaction 
with their medication, when wearing off was experienced 
more than once daily, compared with the group that was 
still satisfied despite experiencing wearing off episodes. 
When initiating polypharmacy in PD, which is very com-
mon even after a short disease duration, consideration must 
be given to its purpose in terms of patient experience. The 
frequent use of selegiline in the Norwegian cohort might be 
due to results of Norwegian research conducted on selegi-
line and published by Larsen et al in the late 1990s.29 This 
introduced another hypothesis, ie, that selegiline might be 
able to modify the progression of early PD.
For a number of newer anti-PD agents, there is evidence 
that improvement of objective measures often translates 
into improvements in quality of life. For instance, enta-
capone resulted in improvement of quality of life in non-
fluctuating patients, but not significantly so in those with 
motor fluctuations.30 Similarly, rasagiline improved quality 
of life as monotherapy in early PD,31 but not significantly 
in its later stages. Taken together, these findings should 
be forwarded to politicians and health care staff through 
seminars, lectures, Internet, and personal contacts in order 
to increase awareness of these issues.
Limitations
Only members of the patient associations of the respective 
countries were eligible for the questionnaire because it was 
distributed together with the journals of the association. 
Patients who join their association may well be more active 
than those who do not. Further, the responders to these 
surveys possibly represent a more active cohort of patients 
and relatives, which may contribute to bias in the study. We 
do not suggest that our findings are valid for the whole PD 
population of the respective countries. Because no national PD 
registries are available, our method was a way to catch a high 
number of patients without contravening the laws concerning 
personal data security or individual integrity. As a limitation 
it is important to mediate that there was no general reminder 
to the questionnaire. Despite this the response rate was high. 
In the Swedish survey, a technical error resulted in no data 
being available on gender. Neither were corresponding data for 
the national association members available in the Norwegian 
survey. However, there is no reason to believe that there should 
be any difference in gender composition or age distribution 
of association members between the two countries.
Conclusion
This study demonstrates differences between countries in 
diagnosing, follow-up, treatment regimens, experience of 
symptoms, and quality of life in patients with PD. Information 
of this kind can be used to compare, evaluate, educate, and 
guide health care staff and administrators to optimize health 
care for patients with PD. The development and implementa-
tion of nationally-based quality registers has been a feature 
of the health care systems of Sweden and Norway for more 
than a decade, and they have now been launched in  Sweden 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
246
Skogar et al
Journal of Multidisciplinary Healthcare
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-multidisciplinary-healthcare-journal
The Journal of Multidisciplinary Healthcare is an international, peer-
reviewed open-access journal that aims to represent and publish research 
in healthcare areas delivered by practitioners of different disciplines. This 
includes studies and reviews conducted by multidisciplinary teams as 
well as research which evaluates the results or conduct of such teams or 
healthcare processes in general. The journal covers a wide range of areas 
and welcomes submission from practitioners at all levels, from all over 
the world. The manuscript management system is completely online and 
includes a very quick and fair peer-review system. Visit http://www.dove-
press.com/testimonials.php to read real quotes from published authors.
Journal of Multidisciplinary Healthcare 2013:6
through the Swedish Movement Disorder Association. 
Future  studies should collect longitudinal data from the same 
patients at appropriate time intervals, given the well known 
risk of an increasing dropout rate. This might be easier and 
more economically performed by web-based procedures, but 
will probably encounter difficulties in obtaining answers from 
older patients because of their inexperience with the Internet. 
Tools for further refining and promoting these processes will 
probably be a core issue in coming decades.
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